Knowledge Center

  • Reset
Oncology Clinical Trials in South Korea: ADC Landscape

11 November 2026

Oncology Clinical Trials in South Korea: ADC Landscape

Oncology clinical trials in South Korea: in-label IITs can target first patient in roughly 3-4 months and build early ADC evidence for global program planning.

Personalized Cancer Vaccines: Lessons from INTerpath-001

27 October 2026

Personalized Cancer Vaccines: Lessons from INTerpath-001

INTerpath-001 is the first positive Phase 3 trial of a personalized cancer vaccine. What it means for trial design, immune monitoring and supply chains.

Why CNS Clinical Trials Fail and How to Adapt

16 October 2026

Why CNS Clinical Trials Fail and How to Adapt

Screen failure, attrition, and heterogeneity in CNS clinical trials often trace back to how the trial is designed, not the underlying biology. Here's what to fix, and when.

7 Alzheimer’s Biomarkers That Inform Trial Design

9 October 2026

7 Alzheimer’s Biomarkers That Inform Trial Design

Deferring biomarker confirmation risks the wrong population or misaligned endpoints. Learn which Alzheimer's biomarkers matter and why to plan early.

7 Decisions That Shape Your Path from Preclinical to Clinical

9 October 2026

7 Decisions That Shape Your Path from Preclinical to Clinical

Your clinical hold rate can hinge on decisions made months before the regulatory submission. Learn 7 preclinical decisions that shape a smooth path to clinical.

First-in-Human vs. First-in-Patient: How to Choose

4 September 2026

First-in-Human vs. First-in-Patient: How to Choose

The first-in-human vs. first-in-patient decision affects your timeline, data, and your next investor conversation. A drug development expert outlines the study choices.

Enhance Your Recruitment & Retention Strategy For Rare Kidney Disease Trials

21 August 2026

Enhance Your Recruitment & Retention Strategy For Rare Kidney Disease Trials

Breakthroughs in genetic understanding alongside the growing shift toward accommodating orphan drugs have led to an upswing in clinical trials for rare kidney disease.

The Rise of Chinese Biotechs and the Global CRO Question

6 August 2026

The Rise of Chinese Biotechs and the Global CRO Question

What's fueling the surge of Chinese biotechs onto the world stage, and what decisions do they face on the path to their first global clinical trial?

How Australia’s Leading CRO Is Driving Biotech’s Acceleration From First-In-Human To Global Markets

27 May 2026

How Australia’s Leading CRO Is Driving Biotech’s Acceleration From First-In-Human To Global Markets

In 2025, Harvill’s experience overseeing CROs through global expansion across Asia Pacific (APAC), Europe, and South America led him to take the helm at Avance Clinical, Australia’s leading CRO.

CNS Trials Are Difficult — Do They Have To Be?

11 March 2026

CNS Trials Are Difficult — Do They Have To Be?

Central nervous system (CNS) indications, including mood disorders, neurodegenerative and neurodevelopmental diseases, and chronic pain, affect more than three billion people worldwide and represent the leading cause of illness and disability globally1.

Why Early CRO Choice Is Critical To Accelerating Delivery Of Your Clinical Program

11 February 2026

Why Early CRO Choice Is Critical To Accelerating Delivery Of Your Clinical Program

Australia's pragmatic regulatory environment, accelerated timelines, globally accepted data, Research and Development Tax Incentive, and other advantages, have emerged as a compelling strategy for Phase I trials.

International Clinical Trials Autumn Issue Is Live

20 November 2025

International Clinical Trials Autumn Issue Is Live

The latest International Clinical Trials (ICT) Autumn Issue is now live, featuring an exclusive interview with Jemma Lawson, Avance Clinical’s Executive Vice President, Global Operations.

Proven industry
experience & expertise

800+

Studies in the past 10 years

500+

Experienced team members

33k+

Participants past 10 years

30

Years of CRO experience